476
Views
92
CrossRef citations to date
0
Altmetric
Research Article

Treatment of neuromuscular and musculoskeletal problems in cerebral palsy

Pages 5-16 | Published online: 10 Jul 2009

References

  • RUSSMAN, B., TILTON, A. and GORMLEY, M.: Cerebral Palsy: A Rational Approach to a Treatment Protocol, and the Role of Botulinum Toxin in Treatment. Muscle and Nerve, S6: S181± S193, 1997.
  • MAHAJAN, D. and DESIRAJU, T.: Alterations of dendritic branch- ing and spine density of hippocampal CA3 pyramidal neurons by operant conditioning in the phase of brain growth support. Experimental Neurology, 100: 1±15, 1988.
  • TRABOULSI, E. and MAUMENEE, I.: Eye problems, In M. D. Frank and A. Oski (editors) (Philadelphia: JB Lippincott), Chapter 34, 1990.
  • MOLNAR, P. (editor) Pediatric Rehabilitatio n, 2nd edn (Baltimore: Williams and Wilkins), p. 512, 1992.
  • LITTLE, J. and MERRITT, J.: Spasticity and associated abnormal- ities of muscle tone. In J. DeLisa (editor) Rehabilitation medicine principles and practice (Philadelphia: JB Lippincott), pp. 430±447, 1988.
  • CHAMBERS, H.: The Surgical Treatment of Spasticity. Muscle and Nerve Supplement, 6: 121, 1997.
  • ALBRIGHT, A. L., et al. : Continuous Intrathecal Baclofen Infusion for Spasticity of Cerebral Origin JAMA, 270: 2475±2477, 1993.
  • PEACOCK, W. and STAUDT, L.: Spasticity in cerebral palsy and the selective posterior rhizotomy procedures. Journal of Child Neurology, 5: 179±185, 1990.
  • O’BRIEN, C., GORMLEY, M. and YABLON, S.: Physiolog y and Management of Spasticity. In Symposium on Physiology and Management of Spasticity (Colorado: Colorado Springs), 1996.
  • ODEEN, I.: Reduction of muscular hypertonus by long-term muscle stretch. Scandinavian Journa l of Rehabilitation Medicine, 13: 93± 99, 1981.
  • MCLAUGHLIN, J. et al. : Efficacy of Selective Dorsal Rhizotomy in Cerebral Palsy: Changes in Mobility after 12 months. Developmental Medicine and Child Neurology, 1996. 38 S(8): p. 4.
  • LEACH, J.: Children Undergoing Treatment with Botulinum Toxin: The Role of the Physical Therapist. Muscle and Nerve, S6: S194±S207, 1997.
  • LEHMANN, J.: Ankle-Foot Orthoses for Paresis and Paralysis. In: G. Kraft (editor) Physical Medicine and Rehabilitatio n Clinics of North America (Philadelphia: Saunders, WB), 1992.
  • HARRIS, S. and RIFFLE, K.: EŒects of inhibitive ankle-foot orthoses on standing balance in a child with cerebral palsy. Physical Therapy, 66: 663±667, 1986.
  • ENGLE, H.: The eŒect of diazepam (Valium) in children with cere- bral palsy: A double-blind study. Developmental Medicine and Child Neurology, 8: 661±667, 1966.
  • GREENE, M. (editor) The Harrient Lane Handboo k, Vol. 14 (St Louis, MO: Mosby Year Book), p. 517, 1996.
  • GRACIES, J. et al. : Traditional Pharmacological Treatments for Spasticity Part II: General and Regional Treatments. Muscle and Nerve, S6: 100, 1997.
  • STEMP IEN, L. and GAEBLER-SPIRA, D.: Rehabilitation of Children and Adults with Cerebral Palsy, In: R. L. Braddom (editor) Physical Medicine and Rehabilitation (Philadelphia: WB Saunders), pp. 1113±1132, 1996.
  • WHYTE, J. and ROBINSON, K.: Pharmacologic Management, In The Practical Management of spasticity in Children and Adults (Philadelphia: Lea and Febiger), p. 209, 1990.
  • KRIEL, R. et al. : Failure of Absorption of Baclofen After Rectal Administration. Pediatric Neurology, 16: 351±352, 1997.
  • REISMAN, M.: Hallucinations association with acute baclofen with- drawal: report of two pediatric cases. 47th Annual Assembly of the American Academy of Physical Medicine and Rehabilitatio n, Kansas City, MO, 1997.
  • HASLAM, R. et al. : Dantrolene sodium in children with spasticity. Archives of Physical Medicine and Rehabilitation, 55: 384±388, 1974.
  • WARD, A., CHAFFMAN, M. and SORKIN, E.: Dantrolene: a review of its pharmacolkinetic properties and therapeutic use in malig- nant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs, 32: 130±168, 1986.
  • PDR, P. G. P.: Dantrolene Sodium, in Physicians’ Desk Reference (Montvale: Medical Economics Company), p. 2540, 1999.
  • LAPIERRE, Y. et al. : Treatment of spasticity with tizanidine in mul- tiple sclerosis. Canadia n Journa l of Neurological Science, 14: 513± 517, 1987.
  • GLENN, M.: Nerve Blocks. In M. Glenn and J. Whyte (editors). The Practical Management of Spasticity in Children and Adults (Philadelphia: Lea and Febiger), p. 230, 1990.
  • EASTON, J., OZ EL, T. and HALP ERN, D.: Intramuscular neurolysis for spasticity in children. Archives of Physical Medicine and Rehabilitation, 60: 156±158, 1984.
  • WOOD, K.: The use of phenol as a neurolytic agent: A review. Pain, 5: 205±229, 1978.
  • MORRISON, J. et al. : Phenol motor point blocks in children: plasma concentrations and cardiac dysrhythmias. Anesthesiology, 75: 359± 362, 1991.
  • SPIRA, R.: Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Developmental Medicine and Child Neurology, 13: 164±173, 1971.
  • KOMAN, L. et al. : Management of cerebral palsy with botulinum A toxin: preliminary investigation (Class C). Journa l of Pediatric Orthopaedics, 13: 489±495, 1993.
  • COSGROVE, A., CORRY, I. and GRAHAM, J.: Botulinum toxin in the management of the lower limb in cerebral palsy (Class C). Developmental Medicine and Child Neurology, 36: 386±396, 1994.
  • SUTHERLAND, D. et al. : Injection of botulinum A toxin into gas- trocnemius muscle of patients with cerebral palsy: a 3D motion analysis study (Class A). Gait & Posture, 1996. 4(4): p. 269±279.
  • KAO, I., DRACHMAN, D. and PRICE, D.: Botulinum toxin: mechan- ism of presynaptic blockade. Science, 193: 1256±1258, 1976.
  • ROSALES, R. et al. : Extrafusal and intrafusal muscle eŒects in experimental botulinum toxin A injection. Muscle and Nerve, 19: 488±496, 1996.
  • BRIN, M. and GROUP, S. S.: Muscle and Nerve. In WE MOVE Spasticity Study Group (Wiley-Interscience Publication), 1997.
  • AOKI, R., et al. : Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait and Posture, in press.
  • SCHANTZ, E. and SCOTT, A.: Use of crystalline type A boulinum toxin in medical research. In G. Lewis (editor) Biomedical aspects of botulism (New York: Academic Press), pp. 143±150, 1981.
  • SCOTT, A. and SUZUKI, D.: Systematic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey. Movement Disorder, 213±217, 1998.
  • YOUNG, R.: Drug therapy: spasticity (®rst of two parts). New England Journa l of Medicine, 304: 28±33, 1981.
  • FORSTER, O.: Uber eine neue operative method der Behadlung spastischer Lahmunger mittels Resektion hinterer Ruckenmarks Wurzeln. Z. Orthop. Chir., 22: 203–223, 1908.
  • FASANO, V. et al. : Functional posterior radiculotomy, in the treat- ment of cerebral spasticity. Perioperative electric stimulation of posterior roots and its use in the choice of the roots to be sec- tioned. Neuro-Chirurgie, 22: 23±34, 1976.
  • PEACOCK, W. and ARENS, L.: Selective posterior rhizotomy for the relief of spasticity in cerebral palsy. South African Medicine Journal, 62: 119±124, 1982.
  • LOGIGIAN, E. et al. : H Re¯ex studies in cerebral palsy patients undergoing partial dorsal rhizotomy. Muscle and Nerve, 5: 539± 549, 1994.
  • STEINBOK, P. et al. : Randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Developmental Medicine and Child Neurology, 39: 178±184, 1997.
  • STOUT, J. et al. : The eŒects of selective dorsal rhizotomy on oxygen consumption and gait velocity in children with cerebral palsy. Developmental Medicine and Child Neurology, Abstracts: 14, 1997.
  • ABEL, N. and SMITH, R. A.: Intrathecal baclofen for treatment of intractable spinal spasticity. Archives of Physical Medicine and Rehabilitation, 75: 54±62, 1994.
  • COFFEE, Y. J. et al. : Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. Journal of Neurosurgery, 78: 226±232, 1993.
  • ALBRIGHT, A. L., BARRY, M. and SCHULTZ, B.: Continuous Intrathecal Baclofen For Generated Dystonia (Children’s Hospital of Pittsburgh), 1996.
  • COOPER, I. et al. : Chronic cerebellar stimulation in cerebral palsy. Neurology, 26: 744±753, 1976.
  • DAVIS, R., BAROLAT-ROMANA, G. and ENGLE, G.: Chronic cere- bellar stimulation for cerebral palsy-®ve year study. Acta Neurochirica Supplement, 30: 317±332, 1980.
  • GAHM, N. et al. : Chronic cerebellar stimulation for cerebral palsy: a double-blind. Neurology, 31: 87±90, 1981.
  • FAHN, S.: High dosage anticholinergic therapy in dystonia. Neurology, 33: 1255±1261, 1983.
  • PAP INI, M., MARTINETTI, M. and PASQUINELLI, A.: Trazodone symptomatic extrapyramidal disorder of infancy and childhood. The Italian Journal of Neurological Sciences, 3: 161±162, 1982.
  • SPEELMAN, D. and VAN MANEN, J.: Cerebral palsy and sterotactic neurosurgery: long term results. Journal of Neurology, Neurosurgery, and Psychiatry, 52: 23±30, 1989.
  • CORRY, I. et al. : Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. Journa l of Pediatric Orthopeadics, 18: 304±311, 1998.
  • GAGE, J.: Gait Analysis in Cerebral Palsy. Clinics in Developmental Medicine, Vol. 121 (New York, Oxford: Blackwell Scienti®c Publications Ltd), p. 122, 1991.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.